10/26/2026
FDA psychedelics docket draws mixed stakeholder responses
Stakeholders express varied opinions on FDA's recent psychedelics docket, highlighting diverse perspectives.
Topic archive
psychedelic alpha
3 stories
9/1/2026
ARPA-H backs ibogaine research amid rising pharma ad spend
Pharmaceutical companies increase ad budgets for psychedelic terms as ARPA-H funds ibogaine studies.
8/21/2026
Johnson & Johnson invests in Delix Therapeutics
Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.